Literature DB >> 12899119

Increased suicide attempt rate among patients interrupting use of atypical antipsychotics.

Ron M Herings1, Joëlle A Erkens.   

Abstract

PURPOSE: The aim of the study is to investigate whether patients at risk to commit suicide could be identified based on their drug refill patterns.
METHODS: Data for this study were obtained from the PHARMO system comprising drug-dispensing data linked to hospital discharge records. All patients aged 15-45 years, suspected to suffer from schizophrenia and exclusive users of olanzapine or risperidone were selected. The use of antipsychotics was converted into treatment episodes of uninterrupted use. Therapy non-compliance was defined as a drug holiday of at least 30 days. The follow-up started with a treatment episode of at least 90 days. Relative risks for suicide attempts and 95% confidence limits due to drug holidays were estimated using Poisson regression analyses.
RESULTS: Of 603 patients, 33% interrupted treatment for at least 30 days. An increased suicide attempt rate was observed when comparing uninterrupted and interrupted drug use (20.0/1000 person years vs 72.1/1000 person years, respectively). A four-fold increased risk for attempting suicide among patients with drug holidays was found (RR adjusted for age and gender 4.2, 95% CI: 1.7-10.1) compared to patients without drug holidays.
CONCLUSIONS: Patients who do not refill atypical antipsychotics in time can be identified in the pharmacy and are most likely those with an increased risk to commit suicide.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12899119     DOI: 10.1002/pds.837

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  25 in total

Review 1.  Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

Authors:  Robert D Gibbons; J John Mann
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

2.  An episode-based framework for analyzing health care expenditures: an application of reward renewal models.

Authors:  E Michael Foster; Fengjuan Xuan
Journal:  Health Serv Res       Date:  2005-12       Impact factor: 3.402

3.  A Comparative Safety Analysis of Medicines Based on the UK Pharmacovigilance and General Practice Prescribing Data in England.

Authors:  Kinan Mokbel; Rob Daniels; Michael N Weedon; Leigh Jackson
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

4.  Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand.

Authors:  Sirijit Suttajit; Sutrak Pilakanta
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

Review 5.  Long-acting risperidone: a review of its use in schizophrenia.

Authors:  Tracy Swainston Harrison; Karen L Goa
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.

Authors:  Y Barak; I Mirecki; H Y Knobler; Z Natan; D Aizenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-02-04       Impact factor: 4.530

Review 7.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

8.  Guideline-concordant antipsychotic use and mortality in schizophrenia.

Authors:  Bernadette A Cullen; Emma E McGinty; Yiyi Zhang; Susan C Dosreis; Donald M Steinwachs; Eliseo Guallar; Gail L Daumit
Journal:  Schizophr Bull       Date:  2012-10-30       Impact factor: 9.306

Review 9.  A scoping review of community pharmacists and patients at risk of suicide.

Authors:  Andrea Lynn Murphy; Katelyn Hillier; Randa Ataya; Pierre Thabet; Anne Marie Whelan; Claire O'Reilly; David Gardner
Journal:  Can Pharm J (Ott)       Date:  2017-10-05

10.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.